[Comment] Augmenting nephroprotection: balcinrenone plus dapagliflozin in chronic kidney disease

The management of chronic kidney disease has undergone a transformation in the past decade following the sequential introduction of SGLT2 inhibitors1 and the non-steroidal MRA finerenone. Guidelines position angiotensin pathway blockers and SGLT2 inhibitors as foundational treatment for proteinuric chronic kidney disease, with non-steroidal MRAs as adjunctive therapy in type 2 diabetes with persistent albuminuria.2,3 This progress notwithstanding, residual disease progression risk remains, especially in patients with persistent albuminuria.